Leading China in the discovery, development, manufacturing and marketing of prescription and OTC medications.

Lotus Pharmaceuticals Inc., based in Beijing, China is a dynamic comprehensive enterprise, which is engaged in the production, trade and retailing of pharmaceuticals. Lotus develops high quality, low cost generic medication and other OTC brands.

On April 17, 2007, Lotus released its 2006 Annual Report, audited by a New York-based public accounting firm. The report revealed $36 million in revenues, $4.1 milion in net profits, and $20.6 in assets. The complete Form 10-KSB may be viewed under SEC filings.

Praising the Company's performance, CEO Dr. Liu Zhongyi expressed: "We firmly believe our existing operations can realize organic growth of 20 percent per year for the coming years. In addition, through complementary acquisitions, we expect to achieve aggregate yearly revenues in excess of $140 million. With expected profit margins of 12-15 percent, after planned acquisitions, Lotus would be on the fast track to leverage the synergy inherent in our enhanced operations. Achieving these objectives should place Lotus amongst the top 100 pharmaceutical companies in China."

This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses.